The metabolic response to hyperglycaemic clamping in insulin-dependent diabetes

Summary The metabolic and hormonal effects of stable hyperglycaemia (10–12 mmol/l) have been examined in five insulin-dependent diabetics and compared with the results of 8 h (1200 to 2000 h) normoglycaemic (5–6 mmol/l) clamping. Glucose levels were maintained using a glucose controlled insulin infusion system. Mean blood lactate, pyruvate, total ketone bodies, glycerol and plasma nonesterified fatty acids were similar during the period of stable glycaemia at the two glucose levels. In contrast mean blood alanine was markedly elevated during hyperglycaemic clamping (0.384 ± 0.008 vs 0.298 ± 0.021 mmol/l) and 3-hydroxybutyrate was slightly decreased (0.068 ± 0.007 vs 0.084 ± 0.008 mmol/l). Plasma glucagon levels were raised during hyperglycaemic clamping and growth hormone slightly decreased. There was a close positive correlation between mean blood alanine and mean blood glucose (r = 0.79, p < 0.01), and a negative correlation of alanine with the amount of insulin infused (r =-0.72, p < 0.01). It is suggested that the raised alanine results from increased peripheral glucose utilisation. In general a short period of stable hyperglycaemia is not associated with a worsening of metabolic abnormalities in insulin-dependent diabetic subjects.     

The ketosis-resistance in fibro-calculous-pancreatic-diabetes. 1. Clinical observations and endocrine-metabolic measurements during oral glucose tolerance test.

We measured circulating levels of C-peptide, pancreatic glucagon, cortisol, growth hormone and metabolites (glucose, non-esterified fatty acids, glycerol and 3-hydroxybutyrate) in fibro-calculous-pancreatic diabetic (FCPD, n = 28), insulin-dependent diabetic (IDDM, n = 28) and non-diabetic control (n = 27) subjects during an oral glucose tolerance test. There was no difference in the two diabetic groups in age (FCPD 24 +/- 2, IDDM 21 +/- 2 years, mean +/- SEM), BMI (FCPD 16.0 +/- 0.6, IDDM 15.7 +/- 0.4 kg/m2), triceps skinfold thickness (FCPD 8 +/- 1, IDDM 7 +/- 1 mm), glycaemic status (fasting plasma glucose, FCPD 12.5 +/- 1.5, IDDM 14.5 +/- 1.2 mmol/l), fasting plasma C-peptide (FCPD 0.13 +/- 0.03, IDDM 0.08 +/- 0.01 nmol/l), peak plasma C-peptide during OGTT (FCPD 0.36 +/- 0.10, IDDM 0.08 +/- 0.03 nmol/l) and fasting plasma glucagon (FCPD 35 +/- 4, IDDM 37 +/- 4 ng/l). FCPD patients, however, showed lower circulating concentrations of non-esterified fatty acids (0.73 +/- 0.11 mmol/l), glycerol (0.11 +/- 0.02 mmol/l) and 3-hydroxybutyrate (0.15 +/- 0.03 mmol/l) compared to IDDM patients (1.13 +/- 0.14, 0.25 +/- 0.05 and 0.29 +/- 0.08 mmol/l, respectively). This could be due to enhanced sensitivity of adipose tissue lipolysis to the suppressive action of circulating insulin and possibly also to insensitivity of hepatic ketogenesis to glucagon. Our results also demonstrate preservation of alpha-cell function in FCPD patients when beta-cell function is severely diminished, suggesting a more selective beta-cell dysfunction or destruction than hitherto believed.     

Comparative effects of two doses of glibenclamide upon metabolic rhythms in maturity-onset diabetics.

Five maturity-onset diabetics have been studied during therapy with glibenclamide 2.5 mg and 5 mg by half-hourly blood sampling for twelve hours. All patients had lower mean blood glucose concentrations during therapy with 5 mg glibenclamide. There was no significant difference between serum insulin concentrations on the two doses, however, serum insulin/blood glucose ratio was higher during the larger dose of glibenclamide. Mean blood lactate, pyruvate and serum triglycerides were significantly lower, and blood glycerol, 3-hydroxybutyrate, and plasma non-esterified fatty acids were increased during therapy with 5 mg. In the individual patient the changes in blood glycerol and plasma non-esterified fatty acids were related to changes in circulating insulin concentration and did not appear to be a true extra-pancreatic effect of glibenclamide. The mechanism of any extra-pancreatic effect remains unclear.     

Lipid abnormalities in untreated maturity-onset diabetics and the effect of treatment

Summary Plasma cholesterol and serum triglyceride levels and frequency of lipoprotein abnormalities were investigated in 126 untreated maturity-onset diabetics and 126 age- and sexmatched control subjects. Serum triglyceride levels were higher (mean: 1.67 mmol/l) and type IV hyperlipoproteinaemia occurred more frequently (16.7%) in the diabetic group as compared with the controls (1.29 mmol/l and 4.8% respectively). These findings were not explained by an excessive frequency of renal disease, hypertension or drug treatment amongst the diabetics. Normal men showed higher serum triglyceride (mean: 1.36mmol/l) and lower plasma cholesterol (mean: 5.6mmol/l) levels than normal women (1.21 mmol/1 and 6.4mmol/l respectively). No sex difference was seen amongst the diabetics. Triglyceride levels fell after one month of dietary treatment but only remained lowered in diabetics who required sulphonylureas for glycaemic control. After treatment for one year the correlation between serum triglycerides and blood glucose rose from r = 0.15 (NS) before treatment to r=0.43 (p<0.001). Similarly the correlation between serum triglycerides and ponderal index rose from r=0.19 (NS) to r=0.28 (p<0.02).     

The acute metabolic effects of glucagon and its interactions with insulin in forearm tissue

Summary The acute effects of glucagon (mol. wt. 3500) and its interactions with insulin were studied in the forearm during eight studies in seven normal, post-absorptive males. The protocol consisted of a 2 h baseline, 1 h glucagon perfusion (mean glucagon increment, 691±50 pg/ml), 1 h perfusion of both insulin and glucagon (mean insulin increment of 105 ±13 mU/l) and a 30 min recovery period. Simultaneous arterial (A), deep venous (DV), and superficial venous (SV) blood samples were obtained at 30 min intervals. Perfusion of glucagon resulted in a decrease in (A-DV) non-esterified fatty acids of-0.128±0.057 mmol/l (n=7, p<0.05) and (A-SV) non-esterified fatty acids of -0.081±0.036 mmol/l (n=7, p<0.05), as well as a change in deep compartment uptake of glycerol after 60 min of -0.044±0.019 mol/min/100 ml of forearm tissue (n=6, p<0.05), indicating increased lipolysis. There was also a decrease in net glucose uptake as reflected by a change in (A-DV) of -0.24±0.09 mmol/l (n=7, p<0.025) and (A-SV) of 0.10± 0.05 mmol/l (n=7, p<0.05). There was also a net decrease in deep arteriovenous differences of potassium in six of seven subjects. Insulin levels, similar to those found after a meal, rapidly reversed the effects of glucagon on non-esterified fatty acid, glucose and potassium. These effects persisted throughout the recovery period.     

ARE HIGH BLOOD SUGAR LEVELS IN THE ELDERLY IGNORED?

Abstract In a survey of 530 patients, aged 75 years and older, who were admitted to a general teaching hospital in Christchurch, 60 (11.3%) were known diabetics. One hundred and seventy-six other patients (33.2%) had a last measured laboratory blood glucose level of >7.8 mmol/l, of whom 27 people (5.1% of all patients) had significant hyperglycemia (over 11 mmol/l). The Geriatric Assessment and Rehabilitation Unit (ARU) and acute general medical wards of the Princess Margaret Hospital made little use of the specialised Diabetes Services for help in managing known or newly diagnosed diabetics. The mean in-hospital laboratory blood glucose value for all diabetics was an unphysiological value of 12.2 mmol/l, compared with a community mean of 4.9 mmol/l and hyperglycemia persisted after resolution of acute medical problems. ARU diabetic patients had significantly lower blood glucose values than those achieved by physicians in acute medical wards. Prescribed medications such as steroids or diuretics contributing to insulin resistance were rarely modified. It is concluded that 16.4% of elderly patients had significant hyperglycemia or poorly managed diabetes mellitus, and that both general and geriatric physicians underestimated both the severity and consequences of elevated blood sugars in older patients in a regional New Zealand community with a ‘high’ diabetes profile. (Aust NZ J Med 1987; 17: 485–490).     

Impaired subcutaneous absorption of insulin in 'brittle' diabetics

Twenty-four hour plasma free insulin and blood glucose and intermediary metabolite profiles have been measured in 6 C-peptide deficient 'brittle' diabetic patients, during continuous sc and im insulin infusion. During sc infusion free insulin profiles were erratic and unpredictable. Mean 24 h blood glucose levels were raised at 12.6 +/- 2.1 (SE) mmol/l, and 3-hydroxybutyrate at 0.24 +/- 0.08 mmol/l. Blood lactate (1.88 +/- 0.18 mmol/l) and glycerol (0.084 +/- 0.007) were also elevated. Insulin (im) restored free insulin profiles to the normal pattern as found in 'stable' diabetics on sc infusion, with characteristic post-meal peaks (49 +/- 7, 103 +/- 35, and 95 +/- 34 mU/l) and stable night-time levels. Mean 24 h blood glucose was 6.7 +/- 1.1 mmol/l (P less than 0-.05 compared to sc infusion) and 3-hydroxybutyrate 0.07 +/- 0.02 mmol/l (P less than 0.05). Blood lactate (1.67 +/- 0.08 mmol/l) and glycerol (0.10 +/- 0.02 mmol/l) levels remained abnormal. The ratio of plasma free insulin to insulin dose administered was significantly higher during im infusion. In the 6 'stable' diabetics on sc insulin infusion good blood glucose control (7.1 +/- 0.9 mmol/l) was accompanied by clear post-prandial insulin peaks, and stable nocturnal levels. The results strongly suggest that in one category of 'brittle' diabetics there is defective and erratic sc insulin absorption.     

Metabolic effects of adrenaline and noradrenaline in man: studies with somatostatin

The metabolic responses to infusion of adrenaline (6 micrograms/min) and of noradrenaline (5 micrograms/min) for 120 minutes have each been studied in five normal males with and without concurrent somatostatin (250 micrograms/h). Adrenaline induced marked and sustained hyperglycaemia (maximal blood glucose at 75 min, 9.0 +/- 0.4 mmol/l) while noradrenaline induced only a mild and transient blood glucose rise. Blood lactate was elevated by adrenaline (2.57 +/- 0.47 mmol/l with adrenaline, 0.62 +/- 0.06 mmol/l with saline at 120 min, p less than 0.02). Pyruvate levels rose proportionately less so that the circulating lactate:pyruvate ratio was increased (16.6 +/- 1.3 with adrenaline, 11.4 +/- 0.9 with saline at 120 min, p less than 0.05). Lactate and pyruvate levels were unaffected by noradrenaline. Both catecholamines increased circulating non-esterified fatty acid (NEFA) and glycerol to peak at 30 min, while maximal 3-hydroxybutyrate concentrations were achieved at 50 min (0.26 +/- 0.07 mmol/l with adrenaline; 0.23 +/- 0.06 mmol/l with noradrenaline; 0.03 +/- 0.01 mol/l with saline, both p less than 0.05). Insulin levels were partially suppressed by noradrenaline, while a small rise in circulating insulin was observed with adrenaline which was also associated with a large rebound rise in insulin secretion on cessation of the infusion. Mild and transient hyperglucagonaemia was observed with adrenaline while stimulation of glucagon secretion was more sustained with noradrenaline. Somatostatin suppressed insulin, glucagon and growth hormone secretion and both magnified and prolonged the hyperglycaemic effect of adrenaline (maximal at 105 min, 11.3 +/- 0.5 mmol/l, p less than 0.01 versus adrenaline alone).(ABSTRACT TRUNCATED AT 250 WORDS)     

The diabetic heart utilizes ketone bodies as an energy source

BackgroundDiabetic heart is characterized by failure of insulin to increase glucose uptake and increasingly relies on free fatty acids (FFAs) as a source of fuel in animal models. However, it is not well known how cardiac energy metabolism is altered in diabetic hearts in humans. We examined cardiac fuel metabolism in the diabetics as compared to non-diabetics who underwent cardiac catheterization for heart diseases.Material and MethodsThe study subjects comprised 81 patients (male 55, female 26, average age 63.0 ± 10.0 years) who underwent the cardiac catheterization for heart diseases. Thirty-six patients were diagnosed as diabetics (diabetic group) and 45 as non-diabetics (non-diabetic group). Blood samplings were done in both the aortic root (Ao) and coronary sinus (CS) simultaneously and the plasma levels of FFAs, glucose, lactate, pyruvate, total ketone bodies and β-hydroxybutyrate were measured and compared between the two groups.ResultsThe myocardial uptake of glucose, lactate and pyruvate were decreased, whereas those of total ketone bodies, β-hydroxybutyrate and acetoacetate were increased in the diabetics as compared to the non-diabetics. However, the myocardial uptakes of FFAs were not significantly increased in the diabetics as compared to the non-diabetics.ConclusionsCardiac uptakes of carbohydrate (glucose, lactate and pyruvate) were decreased, whereas those of total ketone bodies and β-hydroxybutyrate were increased in the diabetics as compared to the non-diabetics in humans. Ketone bodies therefore are utilized as an energy source partially replacing glucose in the human diabetic heart.     

Non-insulin-treated ICA positive and negative diabetics are equally insulin resistant

Insulin action was assessed in 5 cytoplasmic islet cell antibody (ICA) positive non-diabetics, 8 ICA positive (type I) non-insulin-treated diabetics, 7 ICA negative insulin-treated diabetics by measurement of steady state plasma glucose (SSPG) levels during a combined intravenous infusion of propranolol, adrenaline, glucose and insulin. SPPG values of ICA positive and negative non-diabetics were similar and their combined value (4.0 +/- 0.5 mmol/l) was significantly lower (p less than 0.01 and less than 0.01) than those (11.5 +/- 1.9 and 11.3 +/- 2.2 mmol/l) of ICA positive and negative diabetics, indicating that both groups of diabetics were similarly insulin resistant. Similar correlations were observed between SSPG and HbA1 levels when considering all ICA positive subjects (r = 0.89, p less than 0.001) and all ICA negative subjects (r = 0.73, p less than 0.01). Conventional insulin treatment (2.6 months) in 4 ICA positive diabetics improved insulin action in each case with a reduction in mean SSPG concentration from 14.0 +/- 2.3 to 8.5 +/- 3.4 mmol/l. Thus, ICA positive and negative diabetics, of equivalent degree of carbohydrate intolerance, are equally insulin resistant. Insulin treatment may improve, but appears not to normalise, insulin action in ICA positive (type I) diabetics.     

Blood lactate and pyruvate levels in diabetic patients treated with biguanides with and without sulphonylureas

Summary The effect of long-term treatment with phenformin and metformin respectively on blood lactate concentrations in relation to submaximal muscular exercise has been examined in 21 maturity-onset diabetics, using a cross-over method. At similar degrees of diabetic control the mean blood lactate concentration during exercise and shortly thereafter was significantly higher when the patients had received phenformin.The mean fasting lactate concentration was 1.07 mmol/l with phenformin and 1.03 mmol/l with metformin and the peak concentration was 2.56 mmol/l and 2.19 mmol/l respectively. The mean fasting blood glucose concentration before the exercise was 11.2 mmol/l with phenformin and 11.3 mmol/l with metformin; the glucose output in the urine during the preceding 24 hours was 93 mmol and 105 mmol respectively. The mean work load during exercise was 60 watts.     

Regulation of brittle diabetics by a pre-planned insulin infusion programme

Summary Eleven brittle diabetics, mean duration 11.5 years, all treated with highly purified porcine NPH insulin twice daily, were placed on highly purified porcine regular insulin 4 times daily for 2 days. Thereafter pre-planned intravenous insulin infusion was started. Insulin in an amount corresponding to the daily insulin requirement was infused by a mobile electric infusion pump at precalculated rates between 30 and 7 ml/hour during 2 days. The patients were ambulatory. Capillary blood glucose was taken every 30 min after meals and every two hours during the night. After an equilibration period of 7 hours, blood glucose fluctuations were in the physiological range in nearly all patients during the infusion period. [Only 1.3% of the blood samples showed glucose levels lower than 2.5 mmol/l and 2.9% levels exceeding 10.0 mmol/l during the infusion days]. Mean blood glucose (MBG) was 6.0±0.9 mmol/l (mean ± s. d.), the standard deviation of MBG was 1.8±0.5 mmol/l, the mean amplitude of blood glucose excursions (MAGE) 4.7±1.4 mmol/l, and glucosuria 3.1±3.9 g/day. All these data of glucose homeostasis were significantly lower during the infusion days. The incidence of hypoglycaemic attacks was low (0.32/patient/day) and not significantly higher than during NPH treatment. It is concluded that near normal blood glucose fluctuations can be achieved in brittle diabetics by preplanned insulin infusion without `blood glucose monitoring.     

Lack of glucagon response in glucose counter-regulation in Type 1 (insulin-dependent) diabetics: Absence of recovery after prolonged optimal insulin therapy

Summary Mild hypoglycaemia was induced using an artificial pancreas in five normal subjects (from 5.00 ±0.15 to 2.83±0.15 mmol/l) by infusing 28 mU/m² per min soluble insulin for 60 min. Six Type 1 (insulin-dependent) diabetic patients were stabilized for 14h using an artificial pancreas. They were then rendered hypoglycaemic (from 4.94±0.09 to 2.89±0.11 mmol/l) by infusing 28mU/m² per min plus 16 ±3.8mU/min insulin for 60 min. Before the study, the diabetic patients were in optimal blood glucose control (mean blood glucose 6.72±0.11 mmol/l over the previous 14–20 days; HbA₁ 8.3±0.1%). During the insulin infusion test, blood glucose decrement was slower in the diabetic patients than in the control subjects. The blood glucose nadir was delayed in the diabetics until 75 min compared with 55 min in the control subjects. Blood glucose recovery rate in the diabetic subjects was severely impaired. In Type 1 diabetes, the counter-regulatory hormonal response to insulin induced hypoglycaemia is similar to that of non-diabetics, except for that of glucagon, the blunted response of which is not reversed by prolonged optimisation of blood glucose control. This impaired response of the A cell does not seem to be a consequence of insulin deficiency.     

2型糖尿病患者一级亲属非糖尿病者游离脂肪酸水平和代谢特点

目的 探讨2型糖尿病家系一级亲属非糖尿病者血清游离脂肪酸(NEFA)的变化及影响因素.方法 测定186例2型糖尿病患者、565名2型糖尿病家系一级亲属非糖尿病者、149名正常对照者的血脂、血糖及胰岛素水平.结果 (1)一级亲属组空腹NEFA水平明显低于2型糖尿病组[(0.53±0.28 vs 0.63±0.31)mmol/L,P＜0.01],稳态模型评估的胰岛素抵抗指数(HOMA-IR)明显高于正常对照组(0.98±0.51 vs 0.89±0.47,P＜0.01).(2)一级亲属组体重指数(BMI)、血糖及葡萄糖曲线下面积(AUCglu)较高者空腹NEFA明显高于较低者(均P＜0.05).(3)相关分析显示,一级亲属组空腹NEFA与BMI、收缩压、舒张压、AUCglu明显相关(r分别为0.12、0.148、0.21、0.281,均P＜0.05);多元逐步回归分析显示,AUCglu、舒张压、年龄是影响一级亲属组空腹NEFA水平的独立相关因素(均P＜0.01).结论 2型糖尿病家系一级亲属非糖尿病者已经存在胰岛素抵抗,后者与NEFA水平的升高密切相关.     

Significance of plant sterols in diabetes

Plant sterols occur naturally in plants and vegetable oils. Sitosterol and campesterol are markers of cholesterol absorption. The ratio of cholesterol endogenous synthesis to its absorption may be assessed by sitosterol, campesterol and other non-cholesterol sterols (lathosterol and squalen) serum concentration measurements. In 38 Type 2 diabetics (59.9 years, BMI 29.8 kg/m2, HbA1c 7.6%, C-peptid 0.82 nmol/l) and in 40 non-diabetics (37.2 years, BMI 25.4 kg/m2, HbA1c 5.2%, C-peptid 0.85 nmol/l) plant sterols serum concentration were measured: lathosterol (diabetics 10.64, non-diabetics 6.04 mumol/l, p = 0.09), squalen (diabetics 3.42, non-diabetics 1.78 mumol/l, p < 0.01), sitosterol (diabetics 3.91, non-diabetics 3.80 mumol/l, p = 0.60) and campesterol (diabetics 7.91, non-diabetics 8.85 mmol/l, p = 0.09). In non-diabetics squalen positive correlates with C-peptid, lathosterol with triacylglycerols and campesterol with HbA1c. In diabetics correlates diabetes compensation with plant sterols value negative. It seems that plant sterols and probably also cholesterol absorption can be influenced negative by higher value HbA1c.     

A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control

Summary Interruption of a continuous subcutaneous insulin infusion, most often due to technical problems occurring during the night, is a not uncommon event whose metabolic consequences have received relatively little attention until now. We have therefore investigated the changes in blood glucose, plasma non-esterified fatty acids, 3-hydroxybutyrate, glucagon and free insulin in eight C-peptide negative Type 1 diabetic patients whose pumps were deliberately stopped between 23.00 h and 05.00 h. A control test with the pump functioning normally was carried out in each patient and the studies were randomized. Considering the values at 23.00 h as reference, interruption of the insulin infusion resulted in (1) a rapid decrease in plasma free insulin significant after 1 h and reaching a nadir of 6±2 mU/l after 6 h; (2) a rise in blood glucose which was significant at hour 3 and reached 17.4±1.9 mmol/l at hour 6; (3) a moderate increase in plasma non-esterified fatty acids which remained in the range of 700–800 mol/l; (4) an early and linear rise in plasma 3-hydroxybutyrate, significant after 1 h and averaging 1290±140 mol/l after 6 h; (5) a late increase (hour 5) in plasma glucagon. The second aim of our study was to provide for the patient a precise scheme of insulin supplements administered via the pump and based on blood glucose monitoring (Dextrostix — Glucometer) and semi-quantitative evaluation of ketonuria (Acetest). Resetting the pump at its basal rate at 05.00h and giving insulin supplements (2–8 U) at 06.45 h (with the usual breakfast dose) and again at 10.00 h have proved efficacious in restoring satisfactory metabolic control by noon the day after starting the experiment. These results form practical recommendations to patients undergoing this type of accident.     

Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients

Summary The aim of the study was to evaluate an acute decrease in NEFA levels during an oral glucose tolerance test and its effects on glucose tolerance, muscle glucose uptake and muscle indirect calorimetry in ten lean non-insulin-dependent diabetic subjects. Two 75-g oral glucose tolerance tests were performed in random order. Placebo or 250 mg acipimox (to inhibit lipolysis) were administered orally 2 h before the start of the oral glucose tolerance test. Two hours after acipimox administration (time 0), non-esterified fatty acid, glycerol and 3-hydroxybutyrate levels decreased by 84, 68 and 77% respectively, compared to basal levels. Concomitantly, muscle lipid oxidation and non-oxidative glycolysis also decreased significantly. After placebo administration, non-esterified fatty acids, glycerol and 3-hydroxybutyrate and lipid oxidation increased by 29, 28, 106 and 33%, respectively (NS vs basal levels; p<0.001 vs acipimox). There was a negative rate of net glucose storage (interpreted as glycogenolysis) during post-absorptive conditions and at time 0 after administration of both drugs. After oral glucose tolerance test, the incremental areas of blood glucose and insulin were significantly decreased by 18 and 19% after acipimox compared to placebo. In addition, the ratio between the incremental area of forearm muscle glucose uptake and the insulin levels was significantly increased by 45% during acipimox compared to placebo administration. Glucose oxidation and non-oxidative glycolysis were significantly higher while lipid oxidation was significantly lower after acipimox than after placebo. In conclusion, our study found that in lean non-insulin-dependent diabetic subjects, an acute decrease in non-esterified fatty acid levels improves glucose tolerance, muscle glucose uptake, glucose oxidation and non-oxidative glycolysis, but is unable to normalize glucose storage.Abbreviations NEFA Non-esterified fatty acids - NIDDM non-insulin-dependent diabetes mellitus - OGTT oral glucose tolerance test - FMGU forearm muscle glucose uptake - FMBF forearm muscle blood flow - M muscle     

Lack of effects of hyperglycemia on the disposal of 3-hydroxybutyrate in insulin-dependent diabetic patients

There is evidence that hyperketonemia in insulin-dependent diabetes may be aggravated by a decreased disposal rate for ketone bodies. To test the hypothesis that this decrease may be induced by concomitant hyperglycemia through substrate competition at the acetyl-CoA level, 5 young insulin-dependent diabetic subjects received at 2-h iv infusion of 0.9 mmol 3-hydroxybutyrate.kg-1.h-1 at clamped 1. euglycemia (5 mmol/l) and 2. hyperglycemia (11 mmol/l) on separate occasions. To ensure similar metabolic conditions, a low-dose hyperinsulinemic euglycemic clamp was performed during the 5 h preceding the actual studies. Substrate fluxes in muscle were assessed through the forearm technique. The glucose infusion rate was 4.9 and 2.9 mg.kg-1.min-1, and the forearm arteriovenous difference for glucose was 0.72 during hyperglycemia and 0.39 mmol/l (p less than 0.05), during euglycemia. Hyperglycemia did not affect circulating levels of free insulin, glucagon, non-esterified fatty acids, 3-hydroxybutyrate (hyperglycemia: 665, euglycemia: 770 mumol/l, p greater than 0.05) or acetoacetate, nor forearm uptake of 3-hydroxybutyrate (hyperglycemia, 152, euglycemia: 168 mumol/l, p greater than 0.05). In conclusion, our results do not suggest any inhibitory role for hyperglycemia in the disposal of ketone bodies. In as much as extrapolation from the present well insulinized state is appropriate, the data indicate that alternative mechanisms may be involved in the observed impairment of ketone body clearance in hyperketonemic insulin-dependent diabetic patients.     

Hormonal responses to insulin infusion in diabetes mellitus

Summary Twenty diabetic patients and fourteen normal volunteers received infusion of 2.4 U neutral porcine insulin/h until either the blood glucose level was stable, or until hypoglycaemia occurred. As previously reported [1] in the normal group the blood glucose stabilised at 2.8±0.1 mmol/l without any hypoglycaemic symptoms. There was an increase in blood levels of glucagon, cortisol and growth hormone as the blood glucose level fell, the mean peak increments being 167±33 pg/ml, 400±71 nmol/l and 29±7 mU/l, respectively. In ten of the diabetic subjects (Group A) the blood glucose level stabilised at 3.6±0.2 mmol/l during the insulin infusion, with peak increments in plasma glucagon (110±24pg/ml), cortisol (411±71 nmol/l) and growth hormone (22±6 mU/l), not significantly different from those in the normal subjects. These rises in hormone levels occurred during the last hour of infusion after normoglycaemia was reached and maintained. The ten remaining diabetics (Group B) developed symptoms of hypoglycaemia during the infusion. The peak increments in plasma glucagon (19±7 pg/ml), cortisol (183±36 nmol/l) and growth hormone (6±2 mU/l) in this latter group were significantly less than those in the other diabetic group or the normals. The absence of counter-regulatory hormonal responses in the Group B diabetics was related to the development of hypoglycaemia and may be the result of a dysfunction of hypothalamic gluco-regulatory centres.     

Episodic hyperglycaemia in pregnant women with well-controlled Type 1 diabetes mellitus: a major potential factor underlying macrosomia.

AIMS: To test the common assumption that pregnant women who are sufficiently motivated to achieve very good HbA1c levels will record home blood glucose data accurately. METHODS: A new device was used to download information from electronic blood glucose meters to assess the extent of selectivity in patient glucose diary-keeping. RESULTS: In an index case, a woman with excellent ambient HbA1c (5.9%; upper limit of normal 6.1%) was observed to have 68% of preprandial blood glucose readings above the target range of 3.5-6.5 mmol/l and a mean (+/- SD) level of 8.9+/-3.9 mmol/l in the corresponding period. No such impression was conveyed by the home monitoring diary. Six pregnant women with well controlled Type 1 diabetes (mean HbA1c 6.6+/-0.2%) exhibited between 42 and 68% of preprandial readings above the target range. CONCLUSIONS: The frequency of hyperglycaemia has hitherto been underestimated in well controlled pregnant women whose near-perfect home monitoring record is apparently corroborated by near-normal HbA1c levels. These observations provide a hypothesis for understanding of the disappointing continuance of macrosomia despite excellent HbA1c levels throughout pregnancy.